drugset
drugset / Trial / NCT03292536

Merestinib on Bone Metastases in Subjects With Breast Cancer

NCT03292536 ↗

Phase 1 Terminated 2 enrolled University of Utah Eli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment

Summary

This is an open label, pharmacodynamics, intrapatient dose escalation phase 1B study.

Timeline

Start
2018-01-11
Primary completion
2019-06-24
Completion
2019-06-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Merestinib Small molecule 80 mg Oral

Indications

bone neoplasm breast cancer